Onyx Seeks Suitors After Rejecting Amgen’s Bid

REPLAY VIDEO
Your next video will start in
Pause
  • Info

  • Comments

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change